Therapeutic Potential of Endothelial Colony Forming Cells Derived from Human Umbilical Cord Blood

2019 ◽  
Vol 14 (6) ◽  
pp. 460-465 ◽  
Author(s):  
Jing Jia ◽  
Baitao Ma ◽  
Shaoshuai Wang ◽  
Ling Feng

Endothelial progenitor cells (EPCs) are implicated in multiple biologic processes such as vascular homeostasis, neovascularization and tissue regeneration, and tumor angiogenesis. A subtype of EPCs is referred to as endothelial colony-forming cells (ECFCs), which display robust clonal proliferative potential and can form durable and functional blood vessels in animal models. In this review, we provide a brief overview of EPCs’ characteristics, classification and origins, a summary of the progress in preclinical studies with regard to the therapeutic potential of human umbilical cord blood derived ECFCs (CB-ECFCs) for ischemia repair, tissue engineering and tumor, and highlight the necessity to select high proliferative CB-ECFCs and to optimize their recovery and expansion conditions.

2013 ◽  
Vol 91 (6) ◽  
pp. 519-525 ◽  
Author(s):  
Katarzyna Roszek ◽  
Katarzyna Bomastek ◽  
Marian Drożdżal ◽  
Michał Komoszyński

The high quality human mesenchymal stem cells (MSCs) with remarkable expansion potential in culture are demonstrated to possess multifold clinical applications. However, their isolation and characterization are difficult and sometimes ambiguous. We exploited nucleotide metabolizing ecto-enzymes for more complete characterization of MSCs. Using standard methods of cell culturing and analyses, we detected significant differences in the activity of ecto-nucleotidases on the surface of MSCs isolated from umbilical cord tissue and MSC-like cells derived from umbilical cord blood. Interestingly, the proliferation rate and the immunophenotypic characteristics of mesenchymal stem cells also correspond to the activities of these enzymes. Compared with the CD90-, CD105-, and CD73-deficient and slowly proliferating UCB-MSC-like cells that had relatively higher ecto-NTPDases activity, the CD90-, CD105-, and CD73-positive and rapidly proliferating UC-MSCs rather had ecto-5′-nucleotidase activity and presented neither ecto-nucleotidases nor adenylate kinase activities. In summary, our results demonstrate for the first time that activity of purine nucleotide metabolizing ecto-enzymes differs significantly between mesenchymal stem cells drawn from different neonatal sources, corresponding with a distinct proliferative potential.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3911-3911
Author(s):  
David A. Ingram ◽  
Amy Fenoglio ◽  
Laura E. Mead ◽  
Mervin C. Yoder

Abstract Human EPCs are currently defined as a CD133+/Flk1+ subpopulation of CD34+ cells that can be isolated from peripheral blood, bone marrow, and fetal liver (Nature Medicine, 2003). While these cells are widely considered to be EPCs and subsequently used for angiogenic therapies and biomarkers of cardiovascular disease, their proliferative and clonogenic potential has not been compared to other populations of EPCs, which do not express the cell surface antigens, CD34 and AC133. Analogous to a paradigm established in the hematopoietic cell system, we recently developed a single cell clonogenic assay to reproducibly identify the following EPCs: (1) high proliferative potential - endothelial colony forming cells (HPP-ECFC), which form macroscopic colonies that form secondary and tertiary colonies upon replating, (2) low proliferative potential - endothelial colony forming cells (LPP-ECFC), which form colonies greater than 50 cells, but do not form secondary colonies upon replating, (3) endothelial cell clusters (EC-clusters) that contain less than 50 cells, and (4) mature terminally differentiated endothelial cells (EC), which do not divide (Blood, 2004). Utilizing this assay and EPCs derived from human umbilical cord blood mononuclear cells, we compared the clonogenic and proliferative potential of 1,000 single CD34+AC133+Flk1+ and CD34-AC133−Flk1+ umbilical cord blood derived endothelial cells. We conducted four independent experiments. We demonstrate that a complete hierarchy of EPCs can be identified in a population of CD34−AC133−Flk1+ cord blood derived ECs (Table I, n=4). Remarkably, we further show that CD34−AC133−Flk1+ cord blood derived ECs contain more proliferative EPCs (LPP-ECFCs and HPP-ECFCs) compared to CD134+AC133+Flk1+ cord blood derived ECs (Table I, n=4, *p<0.05). In fact, preliminary experiments suggest that CD34−AC133−Flk1+ cells mature into CD34+AC133+Flk1+ cells. Finally, some individual single CD34−AC133−Flk1+ HPP-ECFCs can expand rapidly to 107 cells in ex vivo culture. Retroviral marking of the cell progeny derived from the single cell confirmed that they were derived from the parent cell. Thus, these studies describe the use of a clonogenic assay to identify a novel population of CD34−AC133−Flk1+ EPCs, and preliminary experiments demonstrate that CD34 and AC133 are not universal cell surface markers of the most primitive EPCs. Percent of 1,000 Single Cells Plated Mature EC EC-Cluster LPP-ECFC HPP-ECFC CD34+AC133+Flk1+ ECs 70±11 16±5 10±4 3±1 CD34-AC133-Flk1+ ECs 52±12 17±6 20±3* 10±4*


Stem Cells ◽  
2012 ◽  
Vol 30 (9) ◽  
pp. 1911-1924 ◽  
Author(s):  
Yuchun Liu ◽  
Swee-Hin Teoh ◽  
Mark S. K. Chong ◽  
Eddy S. M. Lee ◽  
Citra N. Z. Mattar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document